Authors: Scott, AM Lee, FT Hopkins, W Cebon, JS Wheatley, JM Liu, ZQ Smyth, FE Murone, C Sturrock, S MacGregor, D Hanai, N Inoue, K Yamasaki, M Brechbiel, MW Davis, ID Murphy, R Hannah, A Lim-Joon, M Chan, T Chong, G Ritter, G Hoffman, EW Burgess, AW Old, LJ

Citation: Am. Scott et al., Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: Results of a phase I trial, J CL ONCOL, 19(19), 2001, pp. 3976-3987

Authors: Gibbs, P Hutchins, AM Dorian, KT Vaughan, HA Davis, ID Silvapulle, M Cebon, JS

Citation: P. Gibbs et al., MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma, MELANOMA RE, 10(3), 2000, pp. 259-264

Authors: Davis, ID Maher, DW Cebon, JS Green, MD Fox, RM McKendrick, JJ Rybak, ME Boyd, AW

Citation: Id. Davis et al., A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer, GROW FACTOR, 17(4), 2000, pp. 287

Authors: Gibbs, P Cebon, JS Calafiore, P Robinson, WA

Citation: P. Gibbs et al., Cardiac metastases from malignant melanoma, CANCER, 85(1), 1999, pp. 78-84